Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Monosialoganglioside - Qilu Pharmaceutical

Next Previous
Drug Profile

Monosialoganglioside - Qilu Pharmaceutical

Alternative Names: GM 1 - Qilu Pharmaceutical; Monosialotetrahexose ganglioside sodium - Qilu Pharmaceutical

Latest Information Update: 19 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qilu Pharmaceutical
  • Class Gangliosides
  • Mechanism of Action Apoptosis inhibitors; Signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ischaemic stroke; Peripheral neuropathies
  • Preclinical Peripheral nervous system diseases

Most Recent Events

  • 13 May 2026 Qilu Pharmaceutical plans a phase II trial for Parkinson's Disease (Treatment-experienced) in May 2026 (Parenteral, Injection) (NCT07585565)
  • 01 Aug 2025 Phase-III clinical trials in Peripheral neuropathies (Neoadjuvant therapy) in China (IV) (NCT06994507)
  • 03 Jun 2025 Qilu Pharmaceutical plans a phase III trial for Peripheral nervous system disease (Second line therapy or greater) (IV, Injection) in July 2025 (NCT06994507)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top